Table 3.

Hazard Ratios of Anti-apoA-1 IgG for Incident Total, Nonfatal, and Fatal CAD According to the C260T rs2569190 Polymorphism Allele Status, in the Genotyped Population

Anti-apoA-1 IgG, HR (95% CI), for CADTotal Incident CAD (n=132)Nonfatal Incident CAD (n=109)Fatal Incident CAD (n=23)
Unadjusted ModelP ValueAdjusted ModelP ValueUnadjusted ModelP ValueAdjusted ModelP ValueUnadjusted ModelP ValueAdjusted ModelP Value
C260T rs2569190 allele status
 CC (n=1097)2.08 (0.98–4.42)0.0562.27 (1.04–4.97)0.0392.19 (0.98–4.87)0.0552.38 (1.03–5.51)0.0421.39 (0.14–13.42)0.7731.55 (0.15–15.81)0.713
 CC/CT (n=3192)1.67 (1.07–2.60)0.0231.77 (1.12–2.80)0.0141.84 (1.14–2.95)0.0121.95 (1.19–3.19)0.0080.91 (0.26–3.17)0.8800.90 (0.24–3.32)0.877
 CT (n=2095)1.55 (0.89–2.68)0.1201.52 (0.86–2.71)0.1521.75 (0.96–3.16)0.0661.73 (0.93–3.23)0.0840.76 (0.17–3.43)0.7180.54 (0.10–3.00)0.486
 TT (n=1055)0.58 (0.20–1.65)0.3060.55 (0.19–1.61)0.2750.74 (0.25–2.14)0.5730.74 (0.25–2.22)0.592No subjectsNo subjects
P value for interaction between anti-apoA-1 IgG and rs2569190 (CC vs CT vs TT)0.0640.0110.1350.033NANA
P value for interaction between anti-apoA-1 IgG and rs2569190 (CC/CT vs TT)0.0680.0200.1260.047NANA
  • Results are expressed as adjusted hazard ratios and (95% confidence interval) for subjects positive (OD>0.64) vs negative (OD<0.64) for anti-apoA-1 IgG. Statistical analysis by Cox proportional hazards regression adjusted for age, sex, systolic blood pressure, diabetes mellitus, smoking, HDL and LDL cholesterol, baseline CAD, statin, β-blocker treatment, and eGFR. The P value for interaction represents the likelihood of interaction between the C260T rs2569190 allele status and the relative anti-apoA-1 IgG effect for coronary artery disease. Anti-apoA-1 IgG indicates anti-apolipoprotein A-1 autoantibodies; CAD, coronary artery disease; CI, confidence interval; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low density lipoprotein; and OD, optical density.